VivoSim Labs (NASDAQ: ONVO)
VivoSim Labs Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
VivoSim Labs Company Info
Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
News & Analysis
Why Organovo Holdings, Inc. Stock Soared 49.7% This Week
The company's licensing agreement with a Swedish company means an infusion of some much-needed cash for Organovo.
Here's Why Organovo Holdings Stock Fell as Much as 28.4% Today
The tissue engineering company reported fiscal fourth-quarter and full-year 2018 results.
Where Will Organovo Holdings, Inc. Be in 5 Years?
Will Organovo unlock the perceived value buried deep in its organ-printing technology by 2022?
Why Tiny Organovo Is Giving Money to Huge Biotech Amgen
Organovo is paying Amgen researchers for their ideas on studying 3D bioprinted tissues. It could be money well spent.
Organovo Holdings Revenue Is Growing at a Snail's Pace Compared With Prior Quarters
The 3D bioprinting company beat analyst revenue estimates in its fiscal first quarter -- but its losses worsened because of higher spending.
How Risky Is Organovo Holdings, Inc.?
Organovo might be less risky than it's been in the past, but this stock still isn't for the faint of heart.
Here's Why Organovo Holdings Inc Fell 10.5% in June
Shares dropped after the company reported uninspiring fourth-quarter results.
3 Reasons Organovo Holdings, Inc. Stock Could Fall Even More
Could the beaten-down 3D bioprinting stock face even worse days ahead?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.